ZNTL
Zentalis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.30
+7.98%Oct 18, 2026, 22:05 UTC
Zentalis Pharmaceuticals, Inc. announced that interim overall survival data from the DENALI Part 1b study were published in an abstract for an upcoming ESMO Congress 2026 presentation.
Source:Aug 13, 2026, 20:01 UTC
Zentalis Pharmaceuticals announced the commencement of a proposed underwritten public offering of shares of its common stock and pre-funded warrants to purchase common stock.